Emergent BioSolutions, Inc.
https://www.emergentbiosolutions.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Emergent BioSolutions, Inc.
US Forming Industry Consortia To Prepare For Future Pandemics And Global Supply Chain Disruptions
HHS agencies look to build on COVID-19 experience by developing quicker public/private responses to pandemics and supply chain threats.
BARDA Lays Out Vision For Next Pandemic: Vaccines For The US Within 130 Days
Federal agency seeks dialogue with industry on how to enable surge capacity for pandemic vaccines without cutting back on other production.One key factor: workforce development.
As Emergent Partnership Dissolves, BARDA Looks To Revamp Post-COVID Pandemic Preparedness
BARDA terminates CIADM contract in wake of vaccine cross-contamination incident, begins discussion with industry about next steps for rapid pandemic response capabilities.
Providence’s COVID-19 mRNA Vaccine Challenger Seen In Phase III In Q1
A possible alternative to Pfizer and Moderna’s COVID-19 vaccines, Providence Therapeutics’ mRNA candidate is seen moving into Phase III trials during the calendar first quarter of next year. While partners Everest Medicines and Biological E have kept the ball rolling, the Canadian biotech will seek further funding, CEO Brad Sorenson tells Scrip in this audio interview.
Company Information
- Industry
-
Pharmaceuticals
- Drug Delivery
- Vaccines
-
Biotechnology
- Large Molecule
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Adapt Pharma Limited
- Aptevo Therapeutics
- BioPort Corporation
- Cangene Corporation
- Trubion Pharmaceuticals, Inc.
- PaxVax Corporation